Literature DB >> 24743445

Evaluation of dexmedetomidine and postoperative pain management in patients with adolescent idiopathic scoliosis: conclusions based on a retrospective study at a tertiary pediatric hospital.

John S Jones1, Richard E Cotugno, Neil Raj Singhal, Neha Soares, Janet Semenova, Sean Nebar, Emily J Parke, M Wade Shrader, Jeffrey Hotz.   

Abstract

OBJECTIVES: This study evaluated the effectiveness of dexmedetomidine in decreasing opioid use in children with adolescent idiopathic scoliosis following posterior spinal fusion surgery at a pediatric tertiary care hospital over the past 10 years.
DESIGN: This was a retrospective chart review. Patients were separated into two groups: those that received opioid via patient-controlled analgesia pain therapy alone and those that received opioid via patient-controlled analgesia pain therapy with dexmedetomidine.
SETTING: A tertiary pediatric free-standing hospital. The study focused on care administered in the perioperative period, including the operating room, ICU, and general hospital floor. PATIENTS: One hundred sixty-three children with adolescent idiopathic scoliosis.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: Measurements included patient demographics, American Society of Anesthesiologists Physical Status Classification System, levels of spinal fusion, length of hospital stay, complications, numeric pain scores, opioid requirement, elastomeric pain pump use, length of time until ambulation, adverse effects, and naloxone use. Data were collected through the first 72 hours of the perioperative period. One hundred six patients received opioids via patient-controlled analgesia therapy with dexmedetomidine and 57 received opioids via patient-controlled analgesia alone. Within the groups, there were 46 patients who received local anesthetic infusions via elastomeric pumps in the patient-controlled analgesia with dexmedetomidine group and 16 patients had pumps in the patient-controlled analgesia-alone group. There was no overall difference in postoperative use of morphine (or equivalents) between the two groups. However, the use of elastomeric pain pumps demonstrated a statistically significant decrease in mean overall opioid consumption (42.6 mg vs 63.1 mg, p < 0.001).
CONCLUSIONS: There was no difference in opioid use related to dexmedetomidine on any postoperative day. The only variable showing a significant opioid sparing effect was the use of local anesthetic infusions via elastomeric pumps. Using continuous local anesthetic infusions instead of dexmedetomidine could eliminate the need for ICU admission, require shorter hospital stays, and reduce costs while still providing safe and effective pain control.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24743445     DOI: 10.1097/PCC.0000000000000119

Source DB:  PubMed          Journal:  Pediatr Crit Care Med        ISSN: 1529-7535            Impact factor:   3.624


  10 in total

Review 1.  [Progress in perioperative pain management of pediatric and adolescent spinal deformity corrective surgery].

Authors:  Haozhong Wang; Peng Xiu; Lei Wang; Yueming Song
Journal:  Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi       Date:  2019-05-15

2.  Intraoperative Dexmedetomidine Promotes Postoperative Analgesia and Recovery in Patients after Abdominal Hysterectomy: a Double-Blind, Randomized Clinical Trial.

Authors:  Dong-Jian Ge; Bin Qi; Gang Tang; Jin-Yu Li
Journal:  Sci Rep       Date:  2016-02-23       Impact factor: 4.379

3.  Dexmedetomidine Improves Postoperative Patient-Controlled Analgesia following Radical Mastectomy.

Authors:  Wei Fan; Hong Xue; Yong Sun; HaiKou Yang; Jun Zhang; Guangming Li; Ying Zheng; Yi Liu
Journal:  Front Pharmacol       Date:  2017-05-09       Impact factor: 5.810

4.  Comparison of the morphine-sparing effect of intraoperative dexmedetomidine with and without loading dose following general anesthesia in multiple-fracture patients: A prospective, randomized, controlled clinical trial.

Authors:  Jin-Ning Zhao; Min Kong; Bin Qi; Dong-Jian Ge
Journal:  Medicine (Baltimore)       Date:  2016-08       Impact factor: 1.889

5.  Comparison of the pro-postoperative analgesia of intraoperative dexmedetomidine with and without loading dose following general anesthesia: A prospective, randomized, controlled clinical trial.

Authors:  Wei Fan; Haikou Yang; Yong Sun; Jun Zhang; Guangming Li; Ying Zheng; Yi Liu
Journal:  Medicine (Baltimore)       Date:  2017-02       Impact factor: 1.889

6.  Efficacy of dexmedetomidine versus midazolam when combined with butorphanol for sedation and analgesia during burn dressing changes: A randomized clinical trial.

Authors:  Xianchao Ding; Hengfeng Cui; Peng Ma; Xi Chen; Yan Sun; Minye Qu; Zhixin Yan
Journal:  Front Pharmacol       Date:  2022-09-07       Impact factor: 5.988

7.  Intraoperative Dexmedetomidine Promotes Postoperative Analgesia in Patients After Abdominal Colectomy: A Consort-Prospective, Randomized, Controlled Clinical Trial.

Authors:  Dong-Jian Ge; Bin Qi; Gang Tang; Jin-Yu Li
Journal:  Medicine (Baltimore)       Date:  2015-09       Impact factor: 1.817

8.  Sex Differences in the Morphine-Sparing Effects of Intraoperative Dexmedetomidine in Patient-Controlled Analgesia Following General Anesthesia: A Consort-Prospective, Randomized, Controlled Clinical Trial.

Authors:  Yuan-Yuan Li; Dong-Jian Ge; Jin-Yu Li; Bin Qi
Journal:  Medicine (Baltimore)       Date:  2016-05       Impact factor: 1.889

9.  Intraoperative Dexmedetomidine Promotes Postoperative Analgesia and Recovery in Patients after Abdominal Colectomy: A CONSORT-Prospective, Randomized, Controlled Clinical Trial.

Authors:  Dong-Jian Ge; Bin Qi; Gang Tang; Jin-Yu Li
Journal:  Medicine (Baltimore)       Date:  2015-10       Impact factor: 1.817

10.  Intravenous Dexmedetomidine Promotes Spinal Bupivacaine Anesthesia and Postoperative Analgesia in Lower Limb Surgery: A Double-Blind, Randomized Clinical CONSORT Study.

Authors:  Hao Zhang; Ming Li; Sai-Yu Zhang; Min Fu; Si-Yan Zhang
Journal:  Medicine (Baltimore)       Date:  2016-02       Impact factor: 1.889

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.